Immune checkpoint inhibitor-induced myopathy has a unique transcriptomic signature, study finds

Transcriptomic analysis has revealed unique characteristics of myopathy induced by immune checkpoint inhibitors (ICIs) that is not seen with other types of myopathy, according to an international group of researchers.

Immune checkpoint inhibitors, which boost the host immune response to cancer cells, have revolutionized the treatment of cancer, the researchers noted.